Informational letter to healthcare professionals regarding the increased risk of immunogenicity in response to the use of the medicinal product PROPES

23.12.2024 624 views

Інформаційний лист-звернення до спеціалістів системи охорони здоров’я з приводу підвищеного ризику розвитку імуногенності у відповідь на застосування лікарського засобу ПРОПЕСPDF · 443 КБ

Завантажити

Informational letter to healthcare professionals regarding the increased risk of immunogenicity in response to the use of the medicinal product PROPES

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration

Informational letter to healthcare professionals regarding the increased risk of immunogenicity in response to the use of the medicinal product PROPES

Other materials in this section

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration